Rondaxe is a drug development services company that strives to take innovative ideas from value creation to value realization. Recognizing the challenges and complexities of drug development in the disciplines covered by “Chemistry, Manufacturing and Controls”, we offer critical expertise, service and software solutions to our customers. Our goal is to effectively help emerging pharmaceutical and biotechnology companies navigate through all phases of the drug development and commercialization process. Customers can choose from our full suite of services and products, or select a specific offering at any point along the drug development timeline. Our philosophy is to be strategic, flexible, hands on and to design a solution based on a customer’s exact set of needs. Rondaxe is the first company to provide a suite of services that combines expert drug development consulting, in-depth project management leadership and software applications designed specifically for emerging pharma/biotechs. Rondaxe is led by four managing members, a team of experienced industry executives and 35 senior advisors, most of whom have 15-35+ years of industry experience, with a vision and an unflinching dedication to our clients’ success. Since our founding in 2003, we have had steady growth because of our proven track record in delivering results, establishing solid relationships with our customers, and a strong commitment to expand our skills and product offerings as our customer’s needs expand.
Looking for a particular Rondaxe Pharma employee's phone or email?
The Rondaxe Pharma annual revenue was $5.7 million in 2026.
Kenton Shultis is the CEO of Rondaxe Pharma.
8 people are employed at Rondaxe Pharma.
Rondaxe Pharma is based in Syracuse, New York.
The NAICS codes for Rondaxe Pharma are [325, 3254, 32, 32541].
The SIC codes for Rondaxe Pharma are [283, 28].